Kymera Therapeutics, Inc. (KYMR): Cost of Revenue

Annual figures by period end, from SEC filings.

$39.21M

Year ended 2025-12-31

$105.00M

Trailing 12 months to 2026-06-30

-5.7%

3-year compound annual growth

2022-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$39.21M	-16.7%	2026-02-26, From 2025-01-01
2024-12-31	$47.07M	-40.1%	2026-02-26, From 2024-01-01
2023-12-31	$78.59M	+67.8%	2026-02-26, From 2023-01-01
2022-12-31	$46.83M	n/a	2025-02-27, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Kymera Therapeutics, Inc. (KYMR)	2025-12-31	$39.21M	-16.7%
X4 Pharmaceuticals, Inc (XFOR)	2025-12-31	$5.76M	+622.3%
Scilex Holding Co (SCLX)	2025-12-31	$10.60M	-36.5%
Protalix BioTherapeutics, Inc. (PLX)	2025-12-31	$26.99M	+11.0%
Champions Oncology, Inc. (CSBR)	2026-04-30	$30.90M	+8.8%
Vir Biotechnology, Inc. (VIR)	2025-12-31	$26.0K	-96.9%
Compugen Ltd (CGEN)	2025-12-31	$9.25M	+16.7%
Recursion Pharmaceuticals, Inc. (RXRX)	2025-12-31	$70.95M	+56.8%
Autolus Therapeutics plc (AUTL)	2025-12-31	$96.37M	+746.3%

Compare KYMR, XFOR, SCLX, PLX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗